

**CURRICULUM VITAE**

A. Personal Information:

Name	Jorge J. Nieva
Business Address	Department of Clinical Medicine USC Norris Comprehensive Cancer Center 1441 Eastlake Ave., Suite 3440 Los Angeles, CA 90033-9173
Business Phone	(323) 865-0421
Business Fax	(323) 865-0061
E-mail Address	<a href="mailto:jorge.nieva@med.usc.edu">jorge.nieva@med.usc.edu</a>
Home Address	1218 Solita Road Pasadena, CA 91103
Home Phone	(406) 371-5797
Citizenship	USA
E-mail Address	<a href="mailto:jnievamt@gmail.com">jnievamt@gmail.com</a>

B. Education:

University	University of California, Irvine, Irvine, CA, Medicine, M.D., 1993-1997 University of California, Irvine, Irvine, CA, Biological Sciences, B.S., 1989-1992
Postgraduate Training	Fellow, Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA, 2000-2003 Resident, Internal Medicine, University of California, San Diego, San Diego, CA, 1998-2000 Internship, Internal Medicine, University of California, San Diego, San Diego, CA, 1997-1998
Honors	Excellence in Research, University of California, Irvine, 1992 American Association of Pathology Chairs Honor Society, 1995 Irving M. Reingold Prize in Pathology, 1995 Walter Blumenson Scholarship for Academic Promise, 1997 Department of Medicine Award, University of California, Irvine, 1997 Alpha Omega Alpha Medical Honors Society, 1997 Waltz Award for Leadership, Scripps Clinic, La Jolla, 2003 Skaggs Scholar in Clinical Science, 2003 Outstanding Teacher Award, Scripps Clinic, La Jolla, 2004 National Cancer Institute Gold Certificate of Excellence, 2011 ASCO Award for Excellence in Clinical Trials, 2012 USC Medical Oncology Faculty Award for Excellence in Teaching, 2015, 2018

C. Professional Background:

## Academic Appointments

Hematologist/Oncologist, The Scripps Clinic, La Jolla, CA, 2003-2007  
Assistant Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, 2003-2007  
Hematologist/Oncologist, The Billings Clinic, Billings, MT, 2007-2014  
Adjunct Professor of Cell Biology, The Scripps Research Institute, La Jolla, CA, 2012-2015  
Associate Professor of Clinical Medicine, University of Southern California, Los Angeles, CA, 2014-present

## Administrative Appointments

Assistant Director, Translational Research, Scripps Cancer Center, La Jolla, CA, 2003-2004  
Director, Andrew J. and Erna F. Viterbi, Department of Translational Research Scripps Cancer Center, La Jolla CA, 2004-2007  
Department Chairman, Hematology/Oncology, Billings Clinic, Billings, MT, 2010-2014  
Section Head, Solid Tumors, USC/Norris Cancer Center 2018-  
Oncology Drug Advisory Committee, United States Food and Drug Administration 2021- 2024

## Teaching

*University of Southern California*

Lecturer, Postgraduate IM Resident Medical Oncology Lectures, 4 Units, Lung & Head/Neck Cancer, 2014-  
Lecturer, Fellow's Lecture Series, 4 Units, Lung & Head/Neck Cancer, 2014-  
Lecturer, Introduction to Clinical Medicine, 12 Units, Cancer Screening, 2014-

*Rocky Mountain College*

Lecturer, Hematology Oncology, 2 Units, Leukemia, 2008-2010

*CME Courses Developed –*

*Western Student and Resident Medical Research Forum*, Executive Co-Director, Western Regional Meetings, 16 Units, 2014-  
*Options and Challenges Related to use of First-line Immunotherapy in Advanced NSCLC*, PeerView Press Virtual Webinar 1 Unit, 2022

## Board Certifications

American Board of Internal Medicine  
Internal Medicine 2003-2033  
Medical Oncology 2006-2036  
Hematology 2006-2023

## Training Record

*Medical Residents*

Sonia Lin, 2014-2016, Disparities in Care of NSCLC  
 Gino In, 2014-2016, Patterns of Metastasis in NSCLC  
 Alexander Martin, 2017-2018, Objective Metrics of Patient Performance in Cancer  
 Arnab Basu 2018-2019, KRAS in lung cancer  
 Jonathan Cheng 2018-2019, Research Biopsies in Cancer Clinical Trials  
 Elizabeth Pan 2018-2019, Validity of Cancer Models in Lung Cancer  
 Christina Vu 2018-2019, CT Screening of Asian Populations for NSCLC  
 Amanda Herrmann 2018-2019, Genomics of Resistance in EGFR/ALK NSCLC  
 Christopher Wang 2020-2022, Objective Measures of Performance Status  
 Karen Resnick 2020-2022, Liquid Biopsy Screening for Lung Cancer  
 Madeline MacDonald 2021-2022, Biopsy Techniques and NGS Success  
 Ronak Patel 2022-2023, Osimertinib induced lung injury

*Graduate Students*

Dena Marrinucci, 2004-2008, Circulating Tumor Cells in Cancer  
 Jeremy Mason, 2012-2016, Markov Modeling of Cancer  
 Paymaneh Malihi, 2015-2019, Predicting outcomes in Prostate Cancer  
 Zaki Hasnain, 2014-2018, Movement Trackers in Evaluation of Cancer Patients  
 Lisa Welter, 2016-2019, Evolution in Breast Cancer  
 Xiayu Jiao, 2017-2019, Pharmaco-economics in lung cancer  
 Joseph Larson 2018-2019, Progression of Breast Cancer in Pseudotime  
 Tanachat Nilanon 2018-2019, Wearable Trackers in Cancer Patients  
 Rishvanth Prabacker 2019, Short Read Sequencing on Long Read Sequencers  
 Ryan Cooper, 2020-2022, Bias in Clinical Trial Enrollment Criteria  
 Raymond Diep, 2022, Biopsy Techniques and NGS success

D. Society Memberships:

## National

American Society of Clinical Oncology, 2003-present  
 American Society of Hematology, 2004-2012  
 American Association for Cancer Research, 2005-2007, 2015-present  
 Digital Medicine Society (DiME) 2021-present

E. Service:

## Department

Thoracic Oncology Program Development, Hoag Cancer Center, 2015  
 Medical Oncology Graduate Medical Education Evaluations Committee, GME, 2015-2016

## Medical School

Resident Research Advisor, Scripps Clinic Graduate Medical Education, LA Jolla, CA, 2003-2007  
Clinical Competency Committee, USC Medical Oncology, 2015-2018

#### Hospital or Medical Group

Cancer Conference Committee Chair, Billings Clinic, Billings, MT, 2007-2014  
Program Leader, Thoracic Oncology, Billings Clinic, Billings, MT, 2007-2014  
Program Leader, Head and Neck Oncology, Billings Clinic, Billings, MT, 2009-2014  
Member, Cancer Committee, Norris Cancer Center, Los Angeles, CA, 2016  
Oncology Strategic Planning Steering Committee, Norris Cancer Hospital, Los Angeles, CA, 2016  
Thoracic Oncology Program Co-Leader  
International Consultant Program, Shenzhen University 2019-2022

#### University

Disease-Site Head, Thoracic and Head & Neck Malignancies, Translational and Clinical Sciences Program, USC/Norris Cancer Center, 2018-  
Reviewer, Clinical Investigations Committee, USC Norris Comprehensive Cancer Center, Los Angeles, CA, 2014-present  
Leadership Committee, USC Norris Comprehensive Cancer Center, Los Angeles, CA, 2016-2017  
Chairman, Data and Safety Monitoring Committee, USC Norris Comprehensive Cancer Center, Los Angeles, CA, 2017-present  
Task Force Member for Equity and Diversity, Keck School of Medicine, Department of Medicine 2019  
Internal Advisory Board, USC-FAMU-UF Cancer Health Equity Center 2019-Present  
Internal Advisory Board, Cancer Research Training Education Center, 2021-Present

#### Professional

Project Team Member, Ixazomib & Pevonedistat, Clinical Trials Network, CTEP, NCI 2017  
Project Team Member, CO-1686 Team, Clinical Trials Network, CTEP, NCI, 2015  
Contributor, Advanced Lung Cancer, Remedy Health Guide, 2017

#### Advisory Boards

Speaker's Bureau, Sanofi-Aventis Inc., 2005  
Clinical Advisory Board, Anaborex Inc., 2005-2007  
Speaker's Bureau, Cytogen Inc., 2006  
Speaker's Bureau, Amgen, 2008-2011  
Speaker's Bureau, Lilly, 2009-2011  
Speaker's Bureau, Boehringer-Ingelheim, 2013-2014  
Scientific Advisory Board, Indee Inc. 2016  
Clinical Advisory Board, Western Oncolytics, 2018  
Scientific Advisory Board, Kyoku Inc 2019  
Scientific Advisory Board, Quantgene Inc. 2019

Clinical Advisory Board, G1 Therapeutics 2022

#### Editorial Boards

Editor, *Convergent Science Physical Oncology*, IOP Publishing, 2014-2017

Associate Editor, *Frontiers in Oncology*, 2019-2021

Guest Editor, *Frontiers in Oncology* 2022-3

#### Journal Reviews

*Convergent Science Physical Oncology*, 2014-2017

*Nature: Scientific Reports*, 2016

*Journal of the National Cancer Institute*, 2016

*BMC Cancer*, 2018

*Clinical and Translational Medicine* 2020

*ASCO's Clinical Cancer Informatics* 2020-2021

*Future Oncology* 2021-2022

*Biomarkers in Medicine* 2021

*Translational Lung Cancer Research* 2021-2022

*JCO, Clinical Cancer Informatics* 2021-2023

*Digital Health* 2021-2022

*JACC:CardioOncology* 2022

#### Grant Reviews

Reviewer, Proteomic Technology Assessment Resources, National Cancer Institute, 2006

Reviewer, Early Detection Research Network, National Cancer Institute, 2010

Reviewer, National Centers for Biomedical Computing, 2010

Reviewer NCI IMAT Innovative and Applied Emerging Technologies in Biospecimen Science, National Cancer Institute, 2012-2014

Reviewer, VA ONCO B Merit Awards, National Cancer Institute, 2014-2015

Reviewer, Exploratory and Developmental Studies, National Cancer Institute 2017

Reviewer, Extramural Loan Repayment Program, National Center for Advancing Translation Sciences, 2017

Reviewer, NCI Omnibus Exploratory Grants Program R21/R03 2018-20

Reviewer, NIH Loan Repayment Program L30/L40 2019-20

Reviewer, NSF Smart and Connected Health Multimodal Sensing P221043 2022

Reviewer, AACR-AstraZeneca Career Development Award for Physician-Scientists, in Honor of José Baselga Scientific Review Committee 2022-3

Reviewer, AACR Immuno-oncology Research Grants Scientific Review Committee 2023

Reviewer, NCI, Biospecimen Science and use of PLCO Biospecimens, 2023

---

## Consultantships

Consultant, Genoptix, Inc., 2005-2006  
Consultant, Genomics Institute of the Novartis Research Foundation, 2005-2007  
Consultant, Alexion Antibody Technologies, 2005-2007  
Consultant, ZLB Behring, 2006  
Consultant, Genentech, 2015  
Consultant, Turnstone Biologics, 2016  
Consultant, Jooster, Inc., 2016-2017  
Consultant, Astra Zeneca, 2017, 2019  
Consultant, Genentech 2017  
Consultant, Takeda 2018  
Consultant, Fujirebio 2019  
Consultant, Mindmed 2021  
Consultant, Ypsomed 2022  
Consultant, Aadi Biosciences 2022  
Consultant, G1 therapeutics 2022  
Consultant, BioAtla 2023  
Consultant, ANP technologies 2023  
Consultant, Sanofi 2023

## Community

Webinar Speaker, Cancer Information and Support Network, Patient Advocates Education, 2015  
Conference Speaker, Community Health Conference, Indian Wells Country Club, Indian Wells, CA, 2015  
Conference Speaker, Hack for Health, University of Southern California, Los Angeles, CA 2017  
Event Chair, Your Next Step is the Cure, Addario Lung Cancer Foundation, San Dimas, CA 2018  
Radio Guest, Cancer Screening, Exitos 99.9, Caracas, Venezuela, 2019  
Invited Speaker, Bravo Magnet High School virtual lecture – Careers in Medicine Los Angeles 2021  
Invited Speaker, Epidemiology of Young Lung Cancer Go2 Foundation Center of Excellence Summit. 2021

## Invited Lectures, Symposia, Keynote Addresses

Keynote Speaker, Cancer Survivor's Day, Scripps Clinic, La Jolla, CA, 2006  
Symposium Speaker, Circulating Tumor Cells, Big Sky ONS, Billings, MT, 2007  
Symposium Speaker, Telemedicine in Oncology, EMTN Retreat, Billings, MT, 2008  
Symposium Speaker, New Oncology Drugs in Development, Big Sky ONS, Billings, MT, 2010  
Symposium Speaker, Clinical Relevance of the Fluid Biopsy, PSOC Annual Meeting, Washington, DC, 2011  
Conference Speaker, HD-CTC Assay: Real Time Fluid Biopsy of Solid Tumors, USC, Los Angeles, CA, 2011  
Symposium Speaker, Clinical Applications of Newton's Model of Metastasis, PSOC Annual Meeting, Washington, DC, 2013

- Symposium Speaker, Getting Access to Data- Lots of Data, BD2K Symposium, Washington, DC, 2014
- Symposium Speaker, Building the Oncology System of the Future, Cancer Center Business Summit, Washington, DC, 2014
- Symposium Speaker, Precision Objective Measures for Cancer, Remote Medicine, and Discovery, Washington, DC, 2017
- Conference Speaker, USC's IMSC Retreat. Digital Applications for Smart Health. Los Angeles 2017
- Conference Speaker, American Cancer Society Cancer Action Network Forum, Challenges in Clinical Trials, Los Angeles, 2017
- Invited Speaker, Los Angeles Otolaryngology Society, Immunotherapy for Head and Neck Cancer, Los Angeles 2018
- Invited Speaker, American Association of Cancer Research Annual Meeting, Opening Plenary Session, Physicist vs Physician, Atlanta, GA 2019
- Invited Speaker, Foundation for the National Institutes of Health Biomarkers Consortium, Cachexia Working Group Workshop, Toward Objective Measures of Performance Status, Bethesda, MD 2019
- Invited Speaker, Los Angeles Radiologic Society Annual Conference, Immunotherapy of Lung Cancer, Long Beach, CA 2019
- Plenary Speaker, American Association of Cancer Research Annual Meeting, Digitizing the Patient, Atlanta 2019
- Invited Speaker, Cachexia Deep Dive Meeting, FNIH, Objective Metrics of Human Performance, North Bethesda, Maryland, 2019
- Invited Speaker, International Society for Biological and Environmental Repositories, Digital Tools that Complement Biobanks, Minneapolis, MN 2019
- Invited Speaker, Digital Innovation to Improve Oncology Clinical Trials and Remote Patient Care in Clinical Trial Partnerships in Oncology virtual conference, 2021
- Invited Speaker, Rethinking Innovation in Cancer Research and Care" -Karnofsky revisited – digital tools to make performance status an objective measure in oncology. Virtual conference 2021
- Invited Speaker, Outcome Measures for Cancer Cachexia, Cancer Cachexia Society Annual Meeting (Clinical Advances in Cancer Cachexia), virtual conference 2021
- Invited Speaker, Hawaii Lung Conference, Real World Evidence, Kona, HI, 2022
- Invited Speaker, Hawaii Lung Conference, Financial Toxicity, Kona, HI, 2022
- Invited Speaker, FLASCO conference on disparities in cancer care, Analyzing Real World Data on Latino and Asian Patients in Los Angeles. Hollywood, FL 2022

#### Invited Grand Rounds/CME Lectures Invited

- Grand Rounds, Circulating Tumor Cells in Predicting Cancer Outcomes, Billings Clinic, Billings, MT, 2008
- Grand Rounds, Personalized Therapy for Lung Cancer, Billings Clinic, Billings, MT, 2009
- Grand Rounds, Lung Cancer Screening, Billings Clinic, Billings MT, 2011
- Grand Rounds, Breast Cancer Update, Livingston Memorial Hospital, Livingston MT, 2011
- Grand Rounds, Novel Immunotherapies for Cancer, Billings Clinic, Billings, MT, 2012

Grand Rounds, Systemic Therapy for NSCLC, Verdugo Hills Hospital, Glendale, CA, 2014  
 CME Lecture, Immunotherapy: USC's Multi-Disciplinary Thoracic Oncology Conference, Pasadena, 2015  
 CME Lecture, Fluid Biopsy: USC's MultiD Thoracic Oncology Conference, Pasadena, CA, 2016  
 CME Lecture, Genomic Testing for Lung Cancer, Who, What, Where, When and How: USC's MultiD Thoracic Oncology Conference, Pasadena, CA 2017  
 CME Lecture, Immunotherapy for Metastatic Lung Cancer, Global Lung Health Summit, Tuscon, AZ 2018  
 Grand Rounds Lecture, Immunotherapy for Metastatic Lung Cancer, Eisenhower Medical Center, Palm Desert, CA 2018  
 CME Lecture, Update on Genomic Testing in Lung Cancer, USC Multidisciplinary Lung Cancer Conference, Marina Del Rey, CA 2019  
 Grand Rounds, Immunotherapy in Non Small Cell Lung Cancer, Huntington Hospital, Pasadena, CA 2019  
 Grand Rounds, Immunotherapy in Metastatic Lung Cancer, Providence Holy Cross Hospital, Mission Hills, CA 2019  
 Department of Medicine Grand Rounds, Toxicity of Cancer Immunotherapy, USC, Los Angeles, CA 91103

F. Research Activities:

Cancer Diagnostic and Prognostic Technologies  
 Mathematical Modeling of Cancer Progression  
 Clinical Trials in Lung Cancer and Head/Neck Cancer  
 Digital Tools for Objective Measurement of Performance Status

G. Research Grants:

Active

1. USC Norris Comprehensive Cancer Center (Core) Grant, P30 CA014089, NIH/NCI, Lerman (PI), Nieva (Chair, DSMC), 12/01/96-11/30/20
2. A phase II study of subcutaneous atezolizumab in NSCLC patients using a decentralized clinical trial model. Nieva (PI)
3. SCH: Wearables for Health and Disease Knowledge, NSF, Shahabi(PI), Nieva (sub-investigator) 1R01LM014026, 1/14/22-12/31/2025
4. Expanding Lung Cancer Immunotherapy by Using TCR T-cells, DoD W81XWH-20-LCRP-IITRA Wang (PI), Nieva (consultant) 9/30/21-9/29/23
5. SU2C Diversity in Early development Clinical Trials Grant Program (El-Khoueiry/Hughes-Halbert Co-PI) Stand Up 2 Cancer Nieva (senior investigator) 01/01/2023-12/31/2024

Completed

1. Impact of COVID-19 on cancer care delivery among diverse populations NCI U54CA233465-03-S2 09/01/20-08/31/22



2. Ming Hseih Foundation, Establishing a Diagnosis of Lung Cancer through a Fluid Biopsy (PI-Kuhn) 2019-2020
3. A Phase IIa Trial of sEphB4-HSA in Combination with Pembrolizumab in Patients with Non-Small Cell Lung and Head/Neck Cancer, #53085 IISP, Merck, Nieva (PI), 04/25/17-04/25/18
4. Four-Dimensional Heterogeneity of Fluid Phase Biopsies in Cancer (4DB Center), U54 CA143906, NIH/NCI, Kuhn (PI), Nieva (Co-Investigator), 09/30/09-08/31/15
5. A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer, #NCIC CTG BR.31, Clinipace, Inc., Nieva (PI), 08/04/15-12/31/20
6. A Phase 1b Multi-Arm Study of sEphB4-HSA in Combination with Different Chemotherapy Regimens in Patients with Advanced Solid Tumors, Whittier Foundation, El-Khoueiry (PI), Nieva (Co-Investigator) 04/01/15-03/31/16
7. Analytic Tools for the Objective Monitoring of Human Performance (ATOM-HP), FFP-012016-0001 (USA051), Noetic Corporation (NIH), Williams (PI), Nieva (PI, Subcontract), 09/30/15-09/29/17
8. Circulating Tumor Cells in Non-Small Cell Lung Cancer, R01 CA125653, NIH/NCI, Nieva (PI), 09/24/07-07/31/12
9. High Speed Reliable Detection of Cancer Cells in Blood, R01 CA111359, NIH/NCI, Bruce (PI), Nieva (Co-Investigator), 09/06/06-07/31/11
10. Investigating the Link between the Atheronals and Aging, R21 AG028300, NIH/NIA, Wentworth (PI), Nieva (Co-Investigator), 08/15/06-06/30/08
11. Pharmacokinetic Effects of Aprepitant on Irinotecan, #26488 IISP, Merck, Nieva (PI), 2005-2007

#### H. Bibliography:

\*author is a mentee of Nieva J

#### Peer Reviewed

1. Stuart MJ, Smith AM, **Nieva JJ**, Rock MG. Injuries in youth ice hockey: a pilot surveillance strategy. *Mayo Clin Proc* 70:350-356, 1995.  
Role: data analysis
2. Wentworth P Jr, McDunn JE, Wentworth AD, Takeuchi C, **Nieva J**, Jones T, Bautista C, Ruedi JM, Gutierrez A, Janda KD, Babior BM, Eschenmoser A, Lerner RA. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. *Science* 298:2195-2199, 2002.  
Role: animal experiments and manuscript writing
3. **Nieva J**, Del Zoppo G. Understanding coagulopathies. *Emerg Med* 35:35-44, 2003.
4. **Nieva J**, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. *Blood* 102:810-813, 2003.

5. Wentworth P Jr, **Nieva J**, Takeuchi C, Galve R, Wentworth AD, Dilley RB, DeLaria GA, Saven A, Babior BM, Janda KD, Eschenmoser A, Lerner RA. Evidence for ozone formation in human atherosclerotic arteries. *Science* 302:1053-1056, 2003.
6. **Nieva J**, Saven A. Cladribine activity in systemic mast cell disease: application of biochemistry in the modern era of molecular biology. *Leuk Res* 28:113-114, 2004.
7. Zhang Q, Powers ET, **Nieva J**, Huff ME, Dendle MA, Bieschke J, Glabe CG, Eschenmoser A, Wentworth P Jr, Lerner RA, Kelly JW. Metabolite-initiated protein misfolding may trigger Alzheimer's disease. *Proc Natl Acad Sci USA* 101:4752-4757, 2004.  
Role: spectrometry experiments and manuscript writing
8. **Nieva J**, Wentworth P Jr. The antibody-catalyzed water oxidation pathway--a new chemical arm to immune defense? *Trends Biochem Sci* 29:274-278, 2004.
9. Mena-Duran AV, Togo SH, Bazhenova L, Cervera J, Bethel K, Senent ML, **Nieva J**, Sanz GF, Sanz MA, Saven A, Mustelin T. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. *Br J Haematol* 129:791-794, 2005.  
Role: Patient enrollment and manuscript writing
10. **Nieva J**, Kerwin L, Wentworth AD, Lerner RA, Wentworth P Jr. Immunoglobulins can utilize riboflavin (Vitamin B2) to activate the antibody-catalyzed water oxidation pathway. *Immunol Lett* 103:33-38, 2006.
11. Hsieh HB, Marrinucci D, Bethel K, Curry DN, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus N, Kuhn P, Bruce RH, **Nieva J**. High speed detection of circulating tumor cells. *Biosens Bioelectron* 21:1893-1899, 2006.
12. Bosco DA, Fowler DM, Zhang Q, **Nieva J**, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. *Nat Chem Biol* 2:249-253, 2006.  
Role: spectroscopy experiments and manuscript writing
13. Takeuchi C, Galve R, **Nieva J**, Witter DP, Wentworth AD, Troseth RP, Lerner RA, Wentworth P Jr. Proatherogenic effects of the cholesterol ozonolysis products, atheronal-A and atheronal-B. *Biochemistry* 45:7162-7170, 2006.  
Role: spectroscopy experiments and manuscript writing
14. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, **Nieva J**, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. *N Engl J Med* 355:1672-1681, 2006.  
Role: patient enrollment and manuscript writing
15. Nerenberg M, Kariv I, McNeeley P, Marchand P, Sur S, Diver J, Riccitelli S, **Nieva J**, Saven A. Use of optophoresis as an *in vitro* predictor of cell response to chemotherapy for chronic lymphocytic leukemia. *Leuk Lymphoma* 47:2194-2202, 2006.

- Role: data analysis and manuscript writing
16. \*Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus NH, **Nieva J**, Kuhn P. Case study of the morphologic variation of circulating tumor cells. *Hum Pathol* 38:514-519, 2007.  
Role: data analysis and manuscript writing
  17. **Nieva J**. The clinical significance of circulating tissue factor in prostate cancer. *Thromb Haemost* 97:329-330, 2007.
  18. **Nieva J**, Saven A. Understanding hairy cell leukemia genetics. *Leuk Lymphoma* 48:653-654, 2007.
  19. Tilley RE, Holscher T, Belani R, **Nieva J**, Mackman N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. *Thromb Res* 122:604-609, 2008. PMID: PMC2572216  
Role: patient enrollment and manuscript writing
  20. **Nieva J**. Genetics of hairy cell leukemia. *Oncol Rev* 1:189-194, 2008. PMID: N/A
  21. **Nieva J**, Shafton A, Altobelli LJ 3rd, Tripuraneni S, Rogel JK, Wentworth AD, Lerner RA, Wentworth P Jr. Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation. *Biochemistry* 47:7695-7705, 2008. PMID: N/A
  22. Martin FM, Prchal J, **Nieva J**, Saven A, Andrey J, Bethel K, Barton JC, Aripally G, Bottomley SS, Friedman JS. Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia. *Br J Haematol* 143:446-450, 2008. PMID: PMC2603068  
Role: data analysis and manuscript writing
  23. Wentworth AD, Song BD, **Nieva J**, Shafton A, Tripuraneni S, Wentworth P Jr. The ratio of cholesterol 5,6-secosterols formed from ozone and singlet oxygen offers insight into the oxidation of cholesterol *in vivo*. *Chem Commun (Camb)* 3098-3100, 2009. PMID: PMC2819220  
Role: spectroscopy experiments and manuscript writing
  24. \*Marrinucci D, Bethel K, Luttgen M, Bruce RH, **Nieva J**, Kuhn P. Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. *Arch Pathol Lab Med* 133:1468-1471, 2009. PMID: PMC4422331  
Role: data analysis and manuscript writing
  25. \*Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P, Bruce R, **Nieva J**, Kuhn P. Cytomorphology of circulating colorectal tumor cells: a small case series. *J Oncol* 2010:861341, 2010. PMID: PMC2810476  
Role: data analysis and manuscript writing

26. **Nieva J**, Song BD, Rogel JK, Kujawara D, Altobel L, 3rd, Izharrudin A, Boldt GE, Grover RK, Wentworth AD, Wentworth P Jr. Cholesterol secosterol aldehydes induce amyloidogenesis and dysfunction of wild-type tumor protein p53. *Chem Biol* 18:920-927, 2011. PMCID: PMC3148486
27. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, **Nieva J**, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. *Nature* 477:99-102, 2011. PMCID: N/A  
Role: patient enrollment and manuscript writing
28. Cho EH, Wendel M, Luttgen M, Yoshioka C, \*Marrinucci D, Lazar D, Schram E, **Nieva J**, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. *Phys Biol* 9:016001, 2012. PMCID: PMC3387999  
Role: data analysis and manuscript writing
29. \*Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, **Nieva J**, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. *Phys Biol* 9:016003, 2012. PMCID: PMC3387996  
Role: data analysis and manuscript writing
30. **Nieva J**, Wendel M, Luttgen MS, \*Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. *Phys Biol* 9:016004, 2012. PMCID: PMC3388002
31. Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, \*Marrinucci D, Sandhu A, Perricone A, Thistlethwaite P, Bethel K, **Nieva J**, Heuvel M, Kuhn P. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. *Phys Biol* 9:016005, 2012. PMCID: PMC3387995  
Role: data analysis and manuscript writing
32. Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, **Nieva JJ**, Wakelee HA, Bruce RH. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. *Lung Cancer* 77:421-426, 2012. PMCID: N/A  
Role: data analysis and manuscript writing

33. Newton PK, \*Mason J, Bethel K, Bazhenova LA, **Nieva J**, Kuhn P. A stochastic Markov chain model to describe lung cancer growth and metastasis. *PLoS One* 7:e34637, 2012. PMID: PMC3338733  
Role: data analysis and manuscript writing
34. Jatoi A, **Nieva JJ**, Qin R, Loprinzi CL, Wos EJ, Novotny PJ, Moore DF Jr, Mowat RB, Bechar N, Pajon ER Jr, Hartmann LC. A pilot study of long-acting octreotide for symptomatic malignant ascites. *Oncology* 82:315-320, 2012. PMID: PMC3559024  
Role: patient enrollment and manuscript writing
35. **Nieva JJ**, Kuhn P. Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease. *Future Oncol* 8:989-998, 2012. PMID: PMC3658625
36. Newton PK, \*Mason J, Bethel K, Bazhenova L, **Nieva J**, Norton L, Kuhn P. Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. *Cancer Res* 73:2760-2769, 2013. PMID: PMC3644026  
Role: data analysis and manuscript writing
37. Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanaawala M, Kuschner W, Bethel K, Iagaru AH, Hoh C, Shrager JB, Loo BW Jr, Bazhenova L, **Nieva J**, Gambhir SS, Kuhn P. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. *PLoS One* 8:e67733, 2013. PMID: PMC3702496  
Role: data analysis and manuscript writing
38. Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, **Nieva J**, Novello S, Ou SH, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. *Cancer* 119:2383-2390, 2013. PMID: PMC3686910  
Role: data analysis and manuscript writing
39. Bazhenova L, Newton P, Mason J, Bethel K, **Nieva J**, Kuhn P. Adrenal metastases in lung cancer: clinical implications of a mathematical model. *J Thorac Oncol* 9:442-446, 2014. PMID: PMC3989547  
Role: data analysis and manuscript writing
40. \*Carlsson A, Nair VS, Luttgen MS, Keu KV, Horng G, Vasanaawala M, Kolatkar A, Jamali M, Iagaru AH, Kuschner W, Loo BW Jr, Shrager JB, Bethel K, Hoh CK, Bazhenova L, **Nieva J**, Kuhn P, Gambhir SS. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. *J Thorac Oncol* 9:1111-1119, 2014. PMID: PMC4145608  
Role: data analysis and manuscript writing
41. Newton PK, \*Mason J, Hurt B, Bethel K, Bazhenova L, **Nieva J**, Kuhn P. Entropy, complexity, and Markov diagrams for random walk cancer models. *Sci Rep* 4:7558, 2014. PMID: PMC4894412

- Role: data analysis and manuscript writing
42. Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M Jr, Saba N, **Nieva J**, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. *Oral Oncol* 51:376-382, 2015. PMID: PMC4459134  
Role: data analysis and manuscript writing
  43. Burke J, **Nieva J**, Borad MJ, Breitbart CJ. Oncolytic viruses: perspectives on clinical development. *Curr Opin Virol* 13:55-60, 2015. PMID: N/A
  44. Role: manuscript writing
  45. **Nieva J**, Bethel K, Baas, C, Kuhn P. Convergent science physical oncology. *Converg Sci Phys Oncol* 1:010201, 2015.
  46. \*In GK, **Nieva J**. Emerging chemotherapy agents in lung cancer: nanoparticle therapeutics for non-small cell lung cancer. *Transl Cancer Res* 4:340-355, 2015.
  47. Newton PK, \*Mason J, Venkatappa N, Jochelson MS, Hurt B, **Nieva J**, Comen E, Norton L, Kuhn P. Spatiotemporal progression of metastatic breast cancer: A Markov chain model highlighting the role of early metastatic sites. *NPJ Breast Cancer* 1:15018, 2015. PMID: PMC5515198  
Role: data analysis and manuscript writing
  48. Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, **Nieva J**, Zhao X, Schell M, Sullivan DM. A randomized Phase II study of Linsitinib (OSI-906) versus Topotecan in patients with relapsed small-cell lung cancer. *Oncologist* 21:1163-1164, 2016. PMID: PMC5061534  
Role: patient enrollment and manuscript writing
  49. Boffa DJ, Graf RP, Salazar MC, Hoag J, Lu D, Krupa R, Louw J, Dugan L, Wang Y, Landers M, Suraneni M, Greene SB, Magana M, Makani S, Bazhenova L, Dittamore RV, **Nieva J**. Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival. *Cancer Epidemiol Biomarkers Prev* 26:1139-1145, 2017. PMID: PMC5500408
  50. \*In GK, Mason J, Lin S, Newton PK, Kuhn P, **Nieva J**. Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. *Converg Sci Phys Oncol* 3:035002, 2017. PMC Journal – In Process
  51. \*Su DW, **Nieva J**. Biophysical technologies for understanding circulating tumor cell biology and metastasis. *Transl Lung Cancer Res* 6:473-485, 2017. PMID: PMC5583073

- 
52. Rodríguez-Lee M, Kolatkar A, McCormick M, Dago AD, Kendall J, \*Carlsson NA, Bethel K, Greenspan EJ, Hwang SE, Waitman KR, **Nieva JJ**, Hicks J, Kuhn P Effect of Blood Collection Tube Type and Time to Processing on the Enumeration and High-Content Characterization of Circulating Tumor Cells Using the High-Definition Single-Cell Assay. Arch Pathol Lab Med. 2018 Feb;142(2):198-207. doi: 10.5858/arpa.2016-0483-OA. Epub 2017 Nov 16. PMID: 29144792
- Role: Study design, patient enrollment, data analysis and manuscript writing
53. **Nieva J**, Hicks J. When it comes to genomic analysis of tumours, don't buy in bulk. Br J Cancer. 2018 May 10. doi: 10.1038/s41416-018-0096-8. [Epub ahead of print] PMID: 29743553
54. \*Hasnain Z, Li M, Dorff T, Quinn D, Ueno NT, Yennu S, Kolatkar A, Shahabi C, Nocera L, **Nieva J**, Kuhn P, Newton PK. Low-dimensional dynamical characterization of human performance of cancer patients using motion data. Clin Biomech (Bristol,Avon). 2018 Jul;56:61-69 PMID 29803824
- Role: data analysis and manuscript writing
55. Yang SC, Welter L, Kolatkar A, **Nieva J**, Waitman KR, Huang KF, Liao WH, Takano S, Berelson WM, West AJ, Kuhn P, John SG. A new anion exchange purification method for Cu stable isotopes in blood samples. Anal Bioanal Chem. 2019 Jan;411(3):765-776. doi: 10.1007/s00216-018-1498-4. Epub 2018 Nov 22. PMID: 30467768
- Role: data analysis and manuscript writing
56. Hassani C, Varghese BA, **Nieva J**, Duddalwar V. Radiomics in Pulmonary Lesion Imaging. AJR Am J Roentgenol. 2019 Mar;212(3):497-504. doi: 10.2214/AJR.18.20623. Epub 2019 Jan 8. PMID: 30620678
- Role: data analysis and manuscript writing
57. Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, Ashkin D, Cheng JH, Lundgren LM, Raabe VN, Kraft CS, **Nieva JJ**, Cheever MA, Nghiem PT, Sharon E. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med. 2019 Jan 16;11(475). pii: eaat2702. doi: 10.1126/scitranslmed.aat2702. PMID: 30651320
- Role: patient enrollment and manuscript writing
58. Jarrell JA, Twite AA, Lau KHWJ, Kashani MN, Lievano AA, Acevedo J, Priest C, **Nieva J**, Gottlieb D, Pawell RS Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding. Sci Rep. 2019 Mar 1;9(1):3214. doi: 10.1038/s41598-019-40147-y. PMID: 30824814
- Role study design and manuscript writing
59. Jonna S, Feldman RA, Swensen J, Gatalica Z, Korn WM, Borghaei H, Ma PC, **Nieva JJ**, Spira AI, Vanderwalde AM, Wozniak AJ, Kim ES, Liu SV. Detection of NRG1 Gene Fusions in Solid Tumors. Clin Cancer Res. 2019 Apr 15. doi: 10.1158/1078-0432.CCR-19-0160 PMID: 30988082
- Role: manuscript writing

60. Ye JC, Ding L, Atay SM, **Nieva JJ**, McFadden PM, Chang E, Kim AW. Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer. *Semin Thorac Cardiovasc Surg.* 2019 Jun 17. pii: S1043-0679(19)30172-8. doi: 10.1053/j.semtcvs.2019.06.002. [Epub ahead of print] PMID: 31220530  
Role: data analysis and manuscript writing
61. Broderick J, May M, Schwartz JE, Li M, Mejia A, Nocera L, Kolatkar A, Ueno NT, Yennu S, Lee J, Hanlon S, Cozzens-Philips FA, Shahabi C, Kuhn P, **Nieva J**. Patient Reported Outcomes Can Improve Performance Status Assessment: A Pilot Study. *J Patient Rep Outcomes.* 2019 Jul 16;3(1):41. PMID: 31313047
62. \*Shishido SN, \*Carlsson A, **Nieva J**, Bethel K, Hicks JB, Bazhenova L, Kuhn P. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. *J Transl Med.* 2019 Aug 28;17(1):294. PMID: 31462312  
Role: data analysis and manuscript writing
63. Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, Sachs BA, **Nieva JJ**, Bertino E, Lee Hann C, Schild SE, Wadsworth TW, Adjei AA, Molina JR. A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study. *J Thorac Oncol.* 2019 Oct 9. pii: S1556-0864(19)33411-2. PMID: 31605793  
Role: patient enrollment and manuscript writing
64. \*Cheng JH, \*Tiulim JW, Zhou S, El-Khoueiry A, **Nieva J**. Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials. *Front Oncol* 2019 Oct 18;9:968 PMID31681560
65. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, **Nieva J**, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM.  
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. *J Thorac Oncol.* 2019 Nov;14(11):1901-1911. PMID: 31446141  
Role: data analysis and manuscript writing
66. \*Shishido SN, \*Welter L, Rodriguez-Lee M, Kolatkar A, Xu L, Ruiz C, Gerdtsen AS, Restrepo-Vassalli S, Carlsson A, \*Larsen J, Greenspan EJ, Hwang ES, Waitman KR, **Nieva J**, Bethel K, Hicks J, Kuhn P. Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients. *J Mol Diagn.* 2020 Mar;22(3):319-337. doi: 10.1016/j.jmoldx.2019.11.006. Epub 2020 Jan 22. PMID: 31978562  
Role: data analysis and manuscript writing



67. Gerdtsen AS, Thiele JA, Shishido SN, Zheng S, Schaffer R, Bethel K, Curley S, Lenz HJ, Hanna DL, **Nieva J**, Kolatkar A, Ruiz C, Rodriguez-Lee M, Oakley Iii GJ, Lee JSH, Hicks J, Kuhn P. Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. *Oncotarget*. 2019 Dec 17;10(66):7016-7030. doi: 10.18632/oncotarget.27271. eCollection 2019 Dec 17. PMID: 31903162  
Role: data analysis and manuscript writing
68. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, **Nieva J**, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol*. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. Erratum in: *Lancet Oncol*. 2020 Feb;21(2):e70. PMID: 31838007  
Role: data analysis and manuscript writing
69. Coyne GO, Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, **Nieva JJ**, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE, Kinders RJ, Piekarczyk RL, Kummar S, Chen AP, Doroshow JH. Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2020 May;85(5):979-993. doi: 10.1007/s00280-020-04073-5. Epub 2020 Apr 20. PMID: 32314030  
Role: patient enrollment and manuscript writing
70. \*Nilanon T, Nocera LP, \*Martin AL, Kolatkar A, May M, \*Hasnain Z, Ueno NT, Yennu S, Alexander A, Mejia AE, \*Boles RW, \*Li M, Lee JS, Hanlon SE, Cozzens Pilips FE, Quinn DI, Newton PK, Broderick J, Shahabi C, Kuhn P, **Nieva JJ**. Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. *JCO Clin Cancer Inform*. 2020 Sep;4:839-853. doi: 10.1200/CCI.29.0023. PMID: 32970482
71. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher Jr GL, Garrido P, **Nieva J**, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol*. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11. PMID: 31838007xx  
Role: patient enrollment and manuscript writing

- 
72. \*Hasnain Z, \*Nilanon T, \*Li M, Mejia A, Kolatkar A, Nocera L, Shahabi C, Cozzens Philips FA, Lee JS, Hanlon SE, \*Vaidya P, Ueno NT, Yennu S, Newton PK, Kuhn P, **Nieva J**. Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. *JCO Clin Cancer Inform*. 2020 Jun;4:583-601. doi: 10.1200/CCI.20.00010. PMID: 32598197
73. \*Pan E, Bogumil D, Cortessis V, \*Yu S, **Nieva J**. A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs. *Front Oncol*. 2020 Apr 23;10:591. doi: 10.3389/fonc.2020.00591. eCollection 2020. PMID: 32391273
74. \*Nilanon T, Nocera LP, **Nieva JJ**, Shahabi C. Towards Automated Performance Status Assessment: Temporal Alignment of Motion Skeleton Time Series. In *Explainable AI in Healthcare and Medicine, Studies in Computational Intelligence*. p335-344. Springer 2020  
Role: study design, patient enrollment, data analysis, manuscript writing
75. \*Green HE, **Nieva J** Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer *Journal of Investigative Medicine*, Published Online First: 14 June 2021. doi: 10.1136/jim-2021-001806
76. Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, Sachs BA, **Nieva JJ**, Bertino E, Lee Hann C, Schild SE, Wadsworth TW, Adjei AA, Molina JR. A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. *J Thorac Oncol*. 2020 Jan;15(1):110-119. doi: 10.1016/j.jtho.2019.09.083. Epub 2019 Oct 9.  
Role: data analysis and manuscript writing
77. \*Welter L, Xu L, McKinley D, Dago AE, Prabakar RK, Restrepo-Vassalli S, Xu K, Rodriguez-Lee M, Kolatkar A, Nevarez R, Ruiz C, **Nieva J**, Kuhn P, Hicks Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. *J Cold Spring Harb Mol Case Stud*. 2020 Dec 17;6(6):a005819. doi: 10.1101/mcs.a005819. Print 2020 Dec. PMID: 33203646  
Role: data analysis and manuscript writing
78. Jonna S, Vanderwalde A, **Nieva J**, Poorman KA, Saul M, von Buttlar X, Hu JY, Liu SV Effect of prior therapy on tumor mutational burden in NSCLC. *Transl Lung Cancer Res*. 2021 Mar;10(3):1231-1238. doi: 10.21037/tlcr-20-1076. PMID: 33889505  
Role: manuscript writing
79. Ris F, Hellan M, Douissard J, **Nieva JJ**, Triponez F, Woo Y, Geller D, Buchs NC, Buehler L, Moenig S, Iselin CE, Karenovics W, Petignat P, Lam GT, Undurraga Malinervo M, Tuttle R, Ouellette J, Bose D, Ismail N, Toso C. Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGENTM): Early Clinical Results. *Cancers (Basel)*. 2021 Aug 15;13(16):4104. doi: 10.3390/cancers13164104. PMID: 34439258

- Role: data analysis and manuscript writing
80. Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, **Nieva JJ**, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). *Lung Cancer*. 2021 Oct;160:92-98. doi: 10.1016/j.lungcan.2021.08.010. Epub 2021 Aug 27. PMID: 34482103  
Role: data analysis and manuscript writing
81. Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, **Nieva JJ**, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G Jr, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. *Mol Cancer Ther*. 2021 Dec;20(12):2577-2584. doi: 10.1158/1535-7163.MCT-21-0201. Epub 2021 Sep 13. PMID: 34518295  
Role: data analysis and manuscript writing
82. \*Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, **Nieva JJ**. Molecular characterization of Kt19-CD133 lung cancer antigen (KLC-1) expressing carcinomas. *Oncotarget*. 2021 Dec 7;12(25):2449-2458. doi: 10.18632/oncotarget.28132. eCollection 2021 Dec 7. PMID: 34917263
83. Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, **Nieva JJ**, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. *Br J Cancer*. 2022 Feb;126(3):514-520. doi: 10.1038/s41416-021-01536-1. Epub 2021 Sep 3. PMID: 34480094  
Role: data analysis and manuscript writing
84. \*Hsu R, \*Herrmann A, \*Gaur K, \*Xia B, **Nieva JJ**. Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles. *Clin Lung Cancer*. 2022 Nov;23(7):e443-e452. doi: 10.1016/j.clcc.2022.06.007. Epub 2022 Jul 4. PMID: 35902325.
85. \*Setayesh SM, Hart O, Naghdloo A, \*Higa N, **Nieva J**, Lu J, Hwang S, Wilkinson K, Kidd M, Anderson A, Velasco CR, Kolatkar A, Matsumoto N, Nevarez R, Hicks JB, Mason J, Shishido SN, Kuhn P. Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. *NPJ Breast Cancer*. 2022 Sep 27;8(1):112. doi: 10.1038/s41523-022-00480-4. PMID: 36167819; PMCID: PMC9515081.  
Role: data analysis and manuscript writing
86. **Nieva J**, Reckamp KL, Potter D, Taylor A, Sun P. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data. *Drugs Real World Outcomes*. 2022

- Sep;9(3):333-345. doi: 10.1007/s40801-022-00302-w. Epub 2022 Jun 3. PMID: 35661118; PMCID: PMC9392819.
87. \*Cooper RA, Chai Y, **Nieva J**. Effect of sponsor on enrollment criteria in non- small cell lung cancer clinical trials. *J Cancer Policy*. 2022 Sep;33:100336. doi: 10.1016/j.jcpo.2022.100336. Epub 2022 May 20. PMID: 35605888.
88. \*Wix SN, **Nieva JJ**. COVID-19 and the acceleration toward remote cancer care. *Proc (Bayl Univ Med Cent)*. 2021 Oct 19;35(2):259-260. doi: 10.1080/08998280.2021.1984814. PMID: 35261474; PMCID: PMC8865276.
89. \*Shishido SN, Sayeed S, Courcoubetis G, Djaladat H, Miranda G, Pienta KJ, **Nieva J**, Hansel DE, Desai M, Gill IS, Kuhn P, \*Mason J. Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer. *Cancers (Basel)*. 2022 Feb 1;14(3):758. doi: 10.3390/cancers14030758. PMID: 35159025; PMCID: PMC8833768.
90. Patel S, Goldsack JC, Cordovano G, Downing A, Fields KK, Geoghegan C, Grewal U, **Nieva J**, Patel N, Rollison DE, Sah A, Said M, Van De Keere I, Way A, Wolff-Hughes DL, Wood WA, Robinson EJ. Advancing Digital Health Innovation in Oncology: Priorities for High-Value Digital Transformation in Cancer Care. *J Med Internet Res*. 2023 Jan 4;25:e43404. doi: 10.2196/43404. PMID: 36598811; PMCID: PMC9850283.  
Role: data analysis and manuscript writing
91. \*Hsu R, Tsai KY, Chennapan K, Wojcik KY, Lee AW, **Nieva JJ**, Liu L. Characterization of mortality and high-risk characteristics of thyroid cancer in Filipinos using the California Cancer Registry. *Front Public Health*. 2023 Jan 19;10:1104607. doi: 10.3389/fpubh.2022.1104607. PMID: 36743179; PMCID: PMC9893642.  
Role: data analysis and manuscript writing
92. Iams WT, Balbach ML, Phillips S, Sacher A, Bestvina C, Velcheti V, Wang X, Marmarelis ME, Sethakorn N, Leal T, Sackstein PE, Kim C, Robinson MA, Mehta K, Hsu R, **Nieva J**, Patil T, Camidge DR. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. *Clin Lung Cancer*. 2023 Feb 8:S1525-7304(23)00018-9. doi: 10.1016/j.clcc.2023.01.009. Epub ahead of print. PMID: 36841727.  
Role: data collection, analysis and manuscript writing
93. Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, Filip E, Pérol M, Besse B, **Nieva J**, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI. TRUST-II: a global phase II study of taletrectinib in *ROS1*-positive non-small-cell lung cancer and other solid tumors. *Future Oncol*. 2023 Mar 6. doi: 10.2217/fon-2022-1059. Epub ahead of print. PMID: 36877099.  
Role: study design and manuscript writing

94. \*Patel R, **Nieva J**. Understanding KRAS for better targeting. *Transl Lung Cancer Res*. 2023 Feb 28;12(2):181-183. doi: 10.21037/tlcr-23-47. Epub 2023 Feb 20. PMID: 36895917; PMCID: PMC9989813.
  
95. Tsui J, Sloan K, Sheth R, Ewusi Boisvert E, **Nieva J**, Kim AW, Pang RD, Sussman S, Kirkpatrick M. Implementation planning for equitable tobacco treatment services: a mixed methods assessment of contextual facilitators and barriers in a large comprehensive cancer center. *Transl Behav Med*. 2023 Mar 20:ibac122. doi: 10.1093/tbm/ibac122. Epub ahead of print. PMID: 36940412.  
Role: study design, data analysis and manuscript writing